Medical News

RSS

Volcano fourth quarter revenues increase 14% to $92.7 million

Volcano Corporation, a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today said revenues in the fourth quarter of 2011 increased 14 percent versus the fourth quarter of 2010.

23 Feb 2012

MannKind net loss for 2011 decreases to $160.8 million

MannKind Corporation today reported financial results for the fourth quarter and year ended December 31, 2011.

23 Feb 2012

Insight into relationship between two types of suppressors in cancerous tumors

The University of Kentucky has announced that Dr. Daret St. Clair, the James Graham Brown Endowed Chair and professor of toxicology, has published the first comprehensive study that provides insight into the relationship between two types of suppressors in cancerous tumors. The results will enhance the understanding of transcriptional mechanisms in carcinogenesis.

23 Feb 2012

Candida albicans can sense immune status of host cells and evade them

Glen Palmer, PhD, Assistant Professor of Microbiology, Immunology & Parasitology at LSU Health Sciences Center New Orleans, was part of an international research team led by Luigina Romani, MD, at the University of Perugia, that discovered opportunistic fungi like Candida albicans can sense the immune status of host cells and adapt, evading immune system defenses.

23 Feb 2012

AHA Heart-Check mark for almonds

The American Heart Association (AHA) recently certified almonds based on their nutrient profile to display the signature Heart-Check mark . The Heart-Check mark is overseen by AHA to help make it easier for shoppers to identify and choose heart-healthy foods.

23 Feb 2012

Targeting versican protein may help stop breast cancer metastasis

Oncologists have known that in order for cancer cells to spread, they must transform themselves so they can detach from a tumor and spread to a distant organ. Now, scientists at Weill Cornell Medical College have revealed critical steps in what happens next -- how these cells reverse the process, morphing back into classical cancer that can now grow into a new tumor.

23 Feb 2012

Allergan's cell-based assay for botulinum toxin type A products receives positive opinions

Allergan is pleased to announce the company has received two positive opinions regarding its fully in vitro, cell-based assay for use in the stability and potency testing of BOTOX and VISTABEL (Allergan's botulinum toxin type A products).

23 Feb 2012

Dolbey launches DocAssist Documentation Guides for hospitals

From the Healthcare Information and Management Systems Society (HIMSS) annual conference, Dolbey introduced DocAssist Documentation Guides to help hospitals train their physicians to document patient reports according to the upcoming ICD-10 PCS requirements.

23 Feb 2012

Accelitech embarks on a proton cancer therapy project

Accelitech LLC, the leader in the development and full-cycle management of technology-driven cancer treatment programs, is pleased to announce its inaugural proton therapy project. The treatment center project, now under development, is the latest in Accelitech's ongoing effort to bring leading treatment technologies to more patients through joint-venture partnerships with physicians and hospitals.

23 Feb 2012

International Microbicides Conference to take place from April 15-18

The biennial International Microbicides Conference is the premier gathering for those working on new approaches to HIV prevention and this year's conference in Sydney, Australia will place a strong emphasis on the role of community in both research and implementation of scientific findings. The conference will take place from April 15-18 at the Sydney Exhibition and Conference Centre located on the Darling Harbour waterfront.

23 Feb 2012

Baron and Budd now offers free wristbands to help raise awareness of mesothelioma

The national mesothelioma law firm of Baron and Budd is now offering free wristbands to help raise awareness of mesothelioma cancer. The wristbands are available here and come in adult and children's sizes.

23 Feb 2012

First-ever comparative analysis of antimalarial medicines at every step of the parasite's life cycle

MMV and partners have completed the first-ever comparative analysis of all currently available and in-development antimalarials in terms of the steps they target in the parasite's lifecycle. This information provides the missing pieces of the puzzle needed to develop future medicines able to block transmission of the parasite from person to person.

23 Feb 2012

FDA EMDAC recommends approval of VIVUS' Qnexa for obesity

VIVUS, Inc. today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults.

23 Feb 2012

Computer-assisted cognitive rehabilitation benefits patients with relapsing-remitting MS

In a new study published in the March issue of Radiology, functional magnetic resonance imaging (fMRI) shows that cognitive rehabilitation changes brain function and improves cognitive performance in patients with relapsing-remitting multiple sclerosis (MS).

23 Feb 2012

IDRI launches LEISH-F3 + GLA-SE Phase 1 trial for kala-azar

The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat diseases of poverty. The Phase 1 trial is taking place in Washington State, with a companion Phase 1 trial planned in India, an epicenter of the disease.

23 Feb 2012

Health Canada accepts Paladin's Silenor NDS for review

Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.

23 Feb 2012

Women with migraine more likely to develop depression

New research suggests women who have migraine or have had them in the past are at an increased risk for developing depression compared to women who have never had migraine.

23 Feb 2012

Depomed, Santarus reach agreement to resolve GLUMETZA patent litigation with Lupin

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a settlement agreement with Lupin Ltd. and its subsidiary, Lupin Pharmaceuticals, Inc., to resolve pending patent litigation involving GLUMETZA 1000 mg and 500 mg.

23 Feb 2012

Chemists build light-controlled neural inhibitor

The notion of a pain switch is an alluring idea, but is it realistic? Well, chemists at LMU Munich, in collaboration with colleagues in Berkeley and Bordeaux, have now shown in laboratory experiments that it is possible to inhibit the activity of pain-sensitive neurons using an agent that acts as a photosensitive switch. For the LMU researchers, the method primarily represents a valuable tool for probing the neurobiology of pain.

23 Feb 2012

New microfluidic device can rapidly isolate target cells

Separating complex mixtures of cells, such as those found in a blood sample, can offer valuable information for diagnosing and treating disease. However, it may be necessary to search through billions of other cells to collect rare cells such as tumor cells, stem cells or fetal cells. "You're basically looking for a needle in a haystack," says Sukant Mittal, a graduate student in the Harvard-MIT Division of Health Sciences and Technology.

23 Feb 2012